- Home
- BDRX vs TCRT Comparison
BDRX vs TCRT Comparison
Compare BDRX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- TCRT
- Stock Information
- Founded
- BDRX 2000
- TCRT 1998
- Country
- BDRX United Kingdom
- TCRT United States
- Employees
- BDRX N/A
- TCRT N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- TCRT Health Care
- Exchange
- BDRX Nasdaq
- TCRT Nasdaq
- Market Cap
- BDRX 3.4M
- TCRT 3.8M
- IPO Year
- BDRX N/A
- TCRT N/A
- Fundamental
- Price
- BDRX $3.80
- TCRT $2.08
- Analyst Decision
- BDRX Strong Buy
- TCRT
- Analyst Count
- BDRX 1
- TCRT 0
- Target Price
- BDRX $200.00
- TCRT N/A
- AVG Volume (30 Days)
- BDRX 55.5K
- TCRT 14.2K
- Earning Date
- BDRX 11-26-2024
- TCRT 11-14-2024
- Dividend Yield
- BDRX N/A
- TCRT N/A
- EPS Growth
- BDRX N/A
- TCRT N/A
- EPS
- BDRX N/A
- TCRT N/A
- Revenue
- BDRX $104,895.00
- TCRT $7,000.00
- Revenue This Year
- BDRX N/A
- TCRT N/A
- Revenue Next Year
- BDRX N/A
- TCRT N/A
- P/E Ratio
- BDRX N/A
- TCRT N/A
- Revenue Growth
- BDRX N/A
- TCRT N/A
- 52 Week Low
- BDRX $3.51
- TCRT $1.95
- 52 Week High
- BDRX $220.25
- TCRT $33.00
- Technical
- Relative Strength Index (RSI)
- BDRX 29.07
- TCRT 44.32
- Support Level
- BDRX $4.70
- TCRT $2.00
- Resistance Level
- BDRX $5.58
- TCRT $2.86
- Average True Range (ATR)
- BDRX 0.48
- TCRT 0.17
- MACD
- BDRX -0.08
- TCRT 0.05
- Stochastic Oscillator
- BDRX 9.03
- TCRT 14.29
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.